Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

Restrict the search for rotigotine to a specific field?

Approximate Matches

25
Related Substance Name

20
Standardized Name

20
Any Name

12
Display Name

9
Reference Text / Citation

4
Note

1
Code Comments

1
Code Literal

1
LACTMED

1
Code URL

1
WIKIPEDIA

1
Relationship Comments

Exact Matches

24
Related Substance Name

2
Display Name

2
Standardized Name

2
Any Name

1
Code Literal

1
LACTMED

1
WIKIPEDIA

Here are the exact (name or code) matches for rotigotine

ROTIGOTINE, (±)-

5QTR54Z0E1

Search for Structure

Status:

Investigational

Source:

NCT00389831: Phase 2 Interventional Completed Restless Legs Syndrome

(2006)

Source URL:

https://clinicaltrials.gov/ct2/show/NCT00389831

Class (Stereo):

CHEMICAL (RACEMIC)

ROTIGOTINE

87T4T8BO2E

Search for Structure

Status:

US Approved Rx (2007)

Source:

NDA021829

(2007)

Source URL:

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021829

First approved in 2007

Source:

NDA021829

Source URL:

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021829

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Dopamine D5 receptor

Dopamine D2 receptor

Dopamine D4 receptor

Dopamine D1 receptor

Dopamine D3 receptor

Serotonin 1a (5-HT1a) receptor

Alpha-2b adrenergic receptor

Conditions:

Restless legs syndrome

Parkinson's disease

Rotigotine is an agonist at all 5 dopamine receptor subtypes (D1-D5) but binds to the D3 receptor with the highest affinity. It is also an antagonist at α-2-adrenergic receptors and an agonist at the 5HT1A receptors. Rotigotine also inhibits dopamine uptake and prolactin secretion. It is FDA approved for the treatment of Parkinson's disease, restless legs syndrome. Dopamine antagonists, such as antipsychotics or metoclopramide, may diminish the effectiveness of Rotigotine. Common adverse reactions include nausea, vomiting, somnolence, application site reactions, dizziness, anorexia, hyperhidrosis, insomnia and dyskinesia.

Showing 1 - 10 of 26 results

First page disabled
Previous page disabled
1
Next page
Next page

ROTIGOTINE

87T4T8BO2E

Search for Structure

Status:

US Approved Rx (2007)

Source:

NDA021829

(2007)

Source URL:

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021829

First approved in 2007

Source:

NDA021829

Source URL:

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021829

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Dopamine D5 receptor

Dopamine D2 receptor

Dopamine D4 receptor

Dopamine D1 receptor

Dopamine D3 receptor

Serotonin 1a (5-HT1a) receptor

Alpha-2b adrenergic receptor

Conditions:

Restless legs syndrome

Parkinson's disease

Rotigotine is an agonist at all 5 dopamine receptor subtypes (D1-D5) but binds to the D3 receptor with the highest affinity. It is also an antagonist at α-2-adrenergic receptors and an agonist at the 5HT1A receptors. Rotigotine also inhibits dopamine uptake and prolactin secretion. It is FDA approved for the treatment of Parkinson's disease, restless legs syndrome. Dopamine antagonists, such as antipsychotics or metoclopramide, may diminish the effectiveness of Rotigotine. Common adverse reactions include nausea, vomiting, somnolence, application site reactions, dizziness, anorexia, hyperhidrosis, insomnia and dyskinesia.

ROTIGOTINE, (±)-

5QTR54Z0E1

Search for Structure

Status:

Investigational

Source:

NCT00389831: Phase 2 Interventional Completed Restless Legs Syndrome

(2006)

Source URL:

https://clinicaltrials.gov/ct2/show/NCT00389831

Class (Stereo):

CHEMICAL (RACEMIC)

DESTHIENYLETHYL ROTIGOTINE SULFATE

C83X2N3S59

Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ABSOLUTE)

(6S)-6-(PROPYL(2-(THIOPHEN-2-YL)ETHYL)AMINO)-5,6,7,8-TETRAHYDRONAPHTHALEN-1-YL ACETATE

97PH4652RU

Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ABSOLUTE)

DESPROPYL ROTIGOTINE

JG1Y5K2S3K

Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ABSOLUTE)

(2S)-5-HYDROXY-N-PROPYL-N-(2-(THIOPHEN-2-YL)ETHYL)-1,2,3,4-TETRAHYDRONAPHTHALEN-2-AMINE N-OXIDE

WB3G8JP37G

Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (EPIMERIC)

(2S)-N-PROPYL-5-(2-(THIOPHEN-2-YL)ETHOXY)-N-(2-(THIOPHEN-2-YL)ETHYL)-1,2,3,4-TETRAHYDRONAPHTHALEN-2-AMINE

23QRX5CL2N

Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ABSOLUTE)

(6S)-6-(PROPYL(2-(THIOPHEN-2-YL)ETHYL)AMINO)-5,6,7,8-TETRAHYDRONAPHTHALEN-1-YL 4-METHYLBENZENESULFONATE

HVH6S4SUP6

Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ABSOLUTE)

(S)-5-METHOXY-N-PROPYL-N-(2-(THIOPHEN-2-YL)ETHYL)-1,2,3,4-TETRAHYDRONAPHTHALEN-2-AMINE

F6E9QF4TQ0

Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ABSOLUTE)

(6S)-6-(ETHYL(2-(2-THIENYL)ETHYL)AMINO)-5,6,7,8-TETRAHYDRO-1-NAPHTHALENOL

BX28WNZ8X5

Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ABSOLUTE)

Structure of ROTIGOTINE

ABSOLUTE

Structure of ROTIGOTINE, (±)-

RACEMIC

ROTIGOTINE, (±)-

Structure of DESTHIENYLETHYL ROTIGOTINE SULFATE

ABSOLUTE

DESTHIENYLETHYL ROTIGOTINE SULFATE

Structure of (6S)-6-(PROPYL(2-(THIOPHEN-2-YL)ETHYL)AMINO)-5,6,7,8-TETRAHYDRONAPHTHALEN-1-YL ACETATE

ABSOLUTE

(6S)-6-(PROPYL(2-(THIOPHEN-2-YL)ETHYL)AMINO)-5,6,7,8-TETRAHYDRONAPHTHALEN-1-YL ACETATE

Structure of DESPROPYL ROTIGOTINE

ABSOLUTE

DESPROPYL ROTIGOTINE

Structure of (2S)-5-HYDROXY-N-PROPYL-N-(2-(THIOPHEN-2-YL)ETHYL)-1,2,3,4-TETRAHYDRONAPHTHALEN-2-AMINE N-OXIDE

EPIMERIC

(2S)-5-HYDROXY-N-PROPYL-N-(2-(THIOPHEN-2-YL)ETHYL)-1,2,3,4-TETRAHYDRONAPHTHALEN-2-AMINE N-OXIDE

Structure of (2S)-N-PROPYL-5-(2-(THIOPHEN-2-YL)ETHOXY)-N-(2-(THIOPHEN-2-YL)ETHYL)-1,2,3,4-TETRAHYDRONAPHTHALEN-2-AMINE

ABSOLUTE

(2S)-N-PROPYL-5-(2-(THIOPHEN-2-YL)ETHOXY)-N-(2-(THIOPHEN-2-YL)ETHYL)-1,2,3,4-TETRAHYDRONAPHTHALEN-2-AMINE

Structure of (6S)-6-(PROPYL(2-(THIOPHEN-2-YL)ETHYL)AMINO)-5,6,7,8-TETRAHYDRONAPHTHALEN-1-YL 4-METHYLBENZENESULFONATE

ABSOLUTE

(6S)-6-(PROPYL(2-(THIOPHEN-2-YL)ETHYL)AMINO)-5,6,7,8-TETRAHYDRONAPHTHALEN-1-YL 4-METHYLBENZENESULFONATE

Structure of (S)-5-METHOXY-N-PROPYL-N-(2-(THIOPHEN-2-YL)ETHYL)-1,2,3,4-TETRAHYDRONAPHTHALEN-2-AMINE

ABSOLUTE

(S)-5-METHOXY-N-PROPYL-N-(2-(THIOPHEN-2-YL)ETHYL)-1,2,3,4-TETRAHYDRONAPHTHALEN-2-AMINE

Structure of (6S)-6-(ETHYL(2-(2-THIENYL)ETHYL)AMINO)-5,6,7,8-TETRAHYDRO-1-NAPHTHALENOL

ABSOLUTE

(6S)-6-(ETHYL(2-(2-THIENYL)ETHYL)AMINO)-5,6,7,8-TETRAHYDRO-1-NAPHTHALENOL

Showing 1 - 10 of 26 results

First page disabled
Previous page disabled
1
Next page
Next page

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1